How long should you take Opicapone?

Opicapone (Opicapone), as an innovative COMT (catechol-O-** transferase) inhibitor, plays an important role in the treatment of patients with Parkinson's disease, especially for those who are experiencing the "off period" (that is, the period during which symptoms relapse and drug efficacy diminishes). The drug is uniquely designed to reduce the decomposition of levodopa in the blood by inhibiting the activity of the COMT enzyme, thereby ensuring that more effective levodopa can cross the blood-brain barrier, enter the brain and exert its neurotransmitter replacement effect, effectively alleviating the symptom fluctuations of patients with Parkinson's disease.

Opicapone has a relatively quick onset of action, and most patients can feel an initial improvement in symptoms within one week of starting treatment, manifested as a shortening of the “off period” and an improvement in overall quality of life. As treatment progresses, the efficacy of Opicapone reaches its peak in the second to third weeks. At this time, patients can often experience a more significant prolongation of the "on" period and a reduction of the "off" period, making daily life and social activities smoother.

Notably, this improvement was not temporary but remained stable over long-term treatment, providing patients with Parkinson's disease with a sustained, reliable symptom management option.

Results from two largePhase III trials show that within a week of starting treatment with Opicapone, it begins to work and that patients who received Opicapone 25 mg daily spent an average of 61 minutes less resting compared to 23 minutes on placebo, and those who received Opicapone 50 mg daily took an average of 75 minutes less time to rest (p=0.0013, P<0.0001, respectively).

Further improvements were observed during the second and third weeks of treatment, after which treatment effects stabilized. At the end of the 14-15 week study, significant reductions in off time were observed of 93 minutes for recipients of Opicapone 25 mg and 120 minutes for recipients of Opicapone 50 mg, compared with a reduction of 55 minutes for placebo recipients (p=0.0091, p<0.001, respectively).